Previous close | 4.4000 |
Open | 4.4000 |
Bid | 4.2000 |
Ask | 4.4000 |
Strike | 105.00 |
Expiry date | 2024-10-18 |
Day's range | 4.4000 - 4.4000 |
Contract range | N/A |
Volume | |
Open interest | 62 |
Primary results of the Scemblix® ASC4FIRST pivotal Phase III study in first-line Ph+ CML-CP supporting third US FDA Breakthrough Therapy designation, to be detailed in the ASCO Press Program and the EHA Plenary SessionLatest data from the Kisqali®* NATALEE trial, including efficacy endpoints for patients with node-negative stage II and III HR+/HER2- early breast cancerNew radioligand therapy portfolio data supporting overall platform leadership and ongoing expansion in research infrastructure an
Q1 2024 Legend Biotech Corp Earnings Call
– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Entered a transaction with Novartis providing an exclusive license for ARV-766 and sale of preclinical AR-V7 program; $150 million upfront payment and potential for